Monitoring and reporting of adverse effects of testosterone prescribing for gender affirmation at general practice clinics - Data from the PUSH! Audit

被引:2
作者
Eu, Beng [1 ,13 ,14 ]
Dawe, Joshua [2 ]
Dunn, Matthew [3 ]
Grace, Julian [4 ]
Lee, Kevin [5 ]
Griffiths, Scott [6 ]
Bloch, Mark [7 ,8 ]
Baker, David [9 ]
Soo, Clara [10 ]
Bisshop, Fiona [11 ]
Stoove, Mark [2 ,5 ,12 ]
机构
[1] Prahran Market Clin, Gen Practice, Melbourne, Australia
[2] Burnet Inst, Epidemiol, Melbourne, Australia
[3] Deakin Univ, Sch Hlth & Social Dev, Melbourne, Vic, Australia
[4] Univ Melbourne, Trans Hlth Res, Melbourne, Australia
[5] Monash Univ, Med Nursing & Hlth Sci, Melbourne, Australia
[6] Univ Melbourne, Sch Psychol Sci, Melbourne, Australia
[7] Univ New South Wales, Med, Sydney, NSW, Australia
[8] Holdsworth House, Gen Practice, Sydney, Australia
[9] East Sydney Doctors, Gen Practice, Sydney, Australia
[10] Hobart Pl Med, Gen Practice, Hobart, Australia
[11] Gen Practice, Holdsworth House, Brisbane, Australia
[12] La Trobe Univ, Australian Res Ctr Sex Hlth & Soc, Melbourne, Australia
[13] Prahran Market Clin, Melbourne, Australia
[14] Univ Melbourne, Melbourne Med Sch, Parkville, Australia
关键词
Adverse effects; GAHT; testosterone; transgender; TERM-FOLLOW-UP; HEALTH-CARE; TRANSGENDER; INDIVIDUALS;
D O I
10.1080/26895269.2023.2271903
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
IntroductionPrescribing testosterone for gender affirming hormone therapy (GAHT) has been increasing in Australia with much of this practice done by general practitioners (GPs) and there are current AusPATH guidelines on how this can be done appropriately. There has been limited data collected from GPs about how well these patients are monitored and the adverse effects (AEs) that are experienced by this population of patients.ObjectivesThe primary objective of this study was to collect data about monitoring and adverse effects of GAHT provided in GP settings.MethodsThe PUSH! Audit was a cross-sectional study that collected data from 9 GP Clinics across 5 Australian cities who provided GAHT with testosterone. Data was also collected about cisgender men who were prescribed testosterone for testosterone deficiency (TD) as a comparison group (n = 209).ResultsThe patients in the GAHT group (n = 277) tended to be younger (29.8 vs 54.9), with significant prevalence of smoking (21.8%) and anxiety/depression (37.2%) although this was not significantly higher that the comparison group. Most of the GAHT group had a testosterone level recorded in their file (90.6%) and the most common route of administration of testosterone was by intra-muscular injection (89.9%). The testosterone levels were mainly in the target range for males (75.7%) with only a small percentage registering levels above the target range (5.6%). Of the measured AEs, whilst there were significant prevalence of liver abnormalities and hypercholesterolemia, this was not significantly different to the TD group. The hypertension prevalence was lower in the GAHT group. Of the reported AEs, acne (10.1%) and balding (4.7%) were the only two AEs that were significantly reported.ConclusionThis study shows that GAHT with testosterone can be provided effectively in general practice with high levels of success and very low levels of AEs.
引用
收藏
页码:770 / 777
页数:8
相关论文
共 21 条
[1]   Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study [J].
Aldridge, Zoe ;
Patel, Shireen ;
Guo, Boliang ;
Nixon, Elena ;
Pierre Bouman, Walter ;
Witcomb, Gemma L. ;
Arcelus, Jon .
ANDROLOGY, 2021, 9 (06) :1808-1816
[2]  
[Anonymous], 2023, Stata Statistical Software: Release 18
[3]   A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones [J].
Asscheman, Henk ;
Giltay, Erik J. ;
Megens, Jos A. J. ;
de Ronde, W. ;
van Trotsenburg, Michael A. A. ;
Gooren, Louis J. G. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2011, 164 (04) :635-642
[4]  
AusPATH, 2022, AUSTR INF CONS STAND
[5]  
Australian Institute of Health and Welfare, 2014, National drug strategy household survey 2013: detailed report
[6]   Transgender and anxiety: A comparative study between transgender people and the general population [J].
Bouman, Walter Pierre ;
Claes, Laurence ;
Brewin, Nicky ;
Crawford, John R. ;
Millet, Nessa ;
Fernandez-Aranda, Fernando ;
Arcelus, Jon .
INTERNATIONAL JOURNAL OF TRANSGENDERISM, 2017, 18 (01) :16-26
[7]   Cross-sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare [J].
Bretherton, Ingrid ;
Thrower, Emily ;
Grossmann, Mathis ;
Zajac, Jeffrey D. ;
Cheung, Ada S. .
INTERNAL MEDICINE JOURNAL, 2019, 49 (02) :182-188
[8]  
Cheung Ada S, 2018, Transgend Health, V3, P229, DOI [10.1089/trgh.2018.0019, 10.1089/trgh.2018.0019]
[9]   Are there additional adverse effects of testosterone use among men living with HIV?-Data from the PUSH! study [J].
Eu, Beng ;
Dawe, Joshua ;
Dunn, Matthew ;
Lee, Kevin ;
Roth, Norman ;
Griffiths, Scott ;
Bloch, Mark ;
Baker, David ;
Soo, Clara ;
Bisshop, Fiona ;
Stoove, Mark .
HIV MEDICINE, 2023, 24 (02) :236-238
[10]  
Hembree WC, 2018, J CLIN ENDOCR METAB, V103, P699, DOI [10.1210/jc.2017-02548, 10.1210/jc.2017-01658]